Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD

Jyotshna Mandal, Michael Roth, Eleni Papakonstantinou, Qingzhu Sun, Luigi Costa, Lucas Boeck, Andreas Scherr, Janko Rakic, Renaud Louis, Branislava Milenkovic, Wim Boersma, Konstantinos Kostikas, Francesco Blasi, Joachim Aerts, Gernot Rohde, Alicia Lacoma, Antoni Torres, Tobias Welte, Michael Tamm, Daiana Stolz

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)111-116
Number of pages6
JournalPulmonary Pharmacology & Therapeutics
Volume48
DOIs
Publication statusPublished - 1 Feb 2018

Keywords

  • Chronic obstructive pulmonary disease (COPD)
  • Irisin
  • Long acting muscarinic receptor antagonist (LAMA)
  • Anticholinergics
  • OBSTRUCTIVE PULMONARY-DISEASE
  • SALMETEROL-FLUTICASONE
  • EXERCISE TOLERANCE
  • RECEPTOR SUBTYPES
  • PARALLEL-GROUP
  • DOUBLE-BLIND
  • TIOTROPIUM
  • MUSCLE
  • GLYCOPYRRONIUM
  • EXACERBATIONS

Cite this

Mandal, J., Roth, M., Papakonstantinou, E., Sun, Q., Costa, L., Boeck, L., Scherr, A., Rakic, J., Louis, R., Milenkovic, B., Boersma, W., Kostikas, K., Blasi, F., Aerts, J., Rohde, G., Lacoma, A., Torres, A., Welte, T., Tamm, M., & Stolz, D. (2018). Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD. Pulmonary Pharmacology & Therapeutics, 48, 111-116. https://doi.org/10.1016/j.pupt.2017.10.011